2018 American Transplant Congress
Clinical Response to Salvage Bortezomib Therapy for Antibody Mediated Rejection and Mixed Acute Rejection in a High Immunologic Risk Renal Transplant Population
University of Illinois at Chicago, Chicago, IL.
Background: Proteasome inhibitor (PI) containing regimens treat antibody mediated rejection (AMR) and mixed acute rejection (MAR) due to elimination of donor specific antibody (DSA). Commonly,…2018 American Transplant Congress
Pre-Emptive Rituximab and Intravenous Immunoglobulin (IVIg) Fail to Prevent Rejection in Kidney Transplant Recipients (KTx) with Donor Specific Antibodies (DSA)
Columbia University, New York, NY.
Introduction:IVIg and Rituximab have been used successfully to improve transplantation rates in sensitized patients. DSA detected by Flow crossmatch (FXM+) or Luminex® at time of…2018 American Transplant Congress
Comparative Analysis of Alloantigen-Stimulated Gene Expression in HIV(+) Liver Transplant Rejectors versus Non-Rejectors
Surgery, University of California, San Francisco, San Francisco, CA.
In a multi-center, prospective trial of solid-organ transplantation in persons with HIV, recipients had a 2-3x increased rejection rate when compared to historical data on…2018 American Transplant Congress
Urinary Proteomics as a Dignostic Mean for Chronic Humoral Rejection after Pediatric Kidney Transplantation
Chronic antibody-mediated rejection (cAMR) is the main cause of long-term graft loss and presents a diagnostic challenge in renal transplantation medicine. Late-stage diagnosis is made…2018 American Transplant Congress
NKG2C+CD57+ NK (G2C+57+) Cells Expanded by CMV Infection Are Highly Responsive to Allo-Antibody (Ab)-Mediated NK Cell Stimulation
Introduction: Active CMV infection is known to be associated with risk for ABMR in allograft recipients. Ab-dependent cellular cytotoxicity (ADCC) primarily mediated by NK cells…2018 American Transplant Congress
Impact of an Anastomosis Time on Transplant Outcomes in Deceased Donor Kidney Transplantation
Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Background: It is known that the increase in anastomosis time (AT) in deceased donor kidney transplantation (DDKT) is associated with increased incidence of delayed graft…2018 American Transplant Congress
Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipients
BACKGROUND: Donor specific antibodies (DSA) have been implicated in the development of acute rejection (AR) and graft dysfunction in kidney transplant recipients (KTx). However, limited…2018 American Transplant Congress
Treatment and Outcomes of Orthotopic Liver Transplant Patients Secondary to Hepatitis C Virus: A Single Center Experience
Background: Treatment of acute cellular rejection (ACR) in patients with orthotopic liver transplantation (OLT) secondary to hepatitis C virus (HCV) remains a major challenge due…2018 American Transplant Congress
Depletion Resistant Effector Memory T Cells Mediate Thymoglobulin Refractory Allograft Rejection in Human Intestinal Transplant Recipients
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC.
A. This study aimed to determine the mechanisms underlying T cell depletion-resistant moderate to severe acute cellular rejection (ACR) in intestinal transplantation (ITx) patients.B. A…2018 American Transplant Congress
Precision Medicine for Determining the Efficacy of a Novel Belatacept Regimen
Transplant Nephrology, UCSF, San Francisco, CA.
IntroBelatacept is increasingly used as maintenance immunosuppression to improve long term outcomes in kidney transplant. Since acute rejection in patients on belatacept have been noted…
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 172
- Next Page »